6505--Buprenorphine Pre-solicitation notice

The Department of Veterans Affairs National Acquisition Center is seeking a supply source for Buprenorphine HCL/Naloxone HCL Sublingual Tablets in two strengths: 2mg/0.5mg and 8mg/2mg, supplied in 30-count bottles. This pharmaceutical procurement will establish a contract to serve the VA and Department of Defense Pharmaceutical Prime Vendor Programs, with participation from the Indian Health Service, Bureau of Prisons, and State Veterans Homes. Offerors must meet FDA requirements, provide a unique 11-digit NDC number, and submit a Letter of Commitment from the manufacturer, along with mandatory pricing that includes a 0.5% Cost Recovery Fee. The solicitation was originally issued on January 6, 2026, with an initial deadline of January 20, 2026, which has been extended twice to February 3, 2026, at 2:30 PM Central Standard Time. Offerors must submit pricing for the base year and all four option years, and must acknowledge receipt of the latest amendment prior to the extended deadline or risk offer rejection.

This is an unrestricted solicitation with a set-aside for small businesses, which have a size standard of 1,300 employees for this category. The estimated annual usage is substantial, with 171,239 bottles anticipated for the 2mg/0.5mg strength and 251,144 bottles for the 8mg/2mg strength, covering a base year plus four option years. Distribution will be handled through prime vendor contractors including McKesson Corporation and other listed distributors. While specific award values are not disclosed in the solicitation notice, the high volume requirements and multi-year contract structure indicate a significant procurement. The contract encompasses nationwide distribution to multiple federal agencies and veteran-serving facilities, with no specific geographic limitation noted for place of performance.